For immediate release
SharePath, The Prescribing Intelligence Company, sets out to retire the decile.
Four first-party fixes help pharma and biotech brands find every prescriber, know what each is worth, and prove what worked.
CARY, N.C. — SharePath, Inc. is The Prescribing Intelligence Company. It helps pharmaceutical and biotechnology brands find every prescriber, know what each is worth, and prove what worked, using first-party data shared directly by clinicians. Its mission is simple: retire the decile™, the ranking the industry has used for decades to decide which prescribers matter.
The decile was built when physicians wrote every script and no one asked AI. Today nurse practitioners and physician associates are the growth driver. Newly licensed prescribers can wait years to reach a call panel. And before many prescribers ever see a rep, they ask AI. The decile often sees none of it.
The same blind spots, everywhere
SharePath’s analysis of 53 brand call panels across 22 therapy areas, from oncology to obesity, found the same gaps at big brands and small ones:
- 93%of call panels missed early-career prescribers.
- 88%were missing a third or more of their NPs and PAs.
- 83%hid a tenfold value gap inside the same decile.
- 58%had specialties wrong, or not listed at all.
“A decile 8 is not a decile 8. Brands are making billion-dollar decisions on data that can’t see who is actually prescribing. Our data isn’t bought or inferred. It’s shared by the clinicians themselves.”
Jeff Wurtsbaugh, Founder and CEO, SharePath
Four fixes. One layer on top of what brands already run.
Each fix sits on top of a brand’s existing data, CRM, agencies and analytics. Nothing is ripped out.
NP/PA Census™
Finds the 43% of NPs and PAs that legacy systems overlook, confirms their real specialty, and scores every one.
TargetMD™
Prescriber valuation that measures beyond the decile, crediting every script to the person who actually wrote it.
PromptPoint™
Shows what prescribers ask AI before a rep arrives, tied to each prescriber and recorded over time.
True ROI™
Everything fixed on the front side, applied to the back side: what promotion actually earned.
Where it started
For more than ten years, SharePath was known as the NP/PA marketing company for pharma. That work made NPs and PAs, the hardest prescribers to see, SharePath’s Center of Excellence, and it built the foundation for everything the company does today.
Two divisions, one first-party foundation
SharePath operates in two divisions. Intelligence (SharePath) serves life sciences brands. Engagement (Health-Scripts®) is a network of 650,000+ verified MDs, DOs, NPs and PAs, built over more than a decade. Member clinicians share how they practice, under contract. That is what makes SharePath’s data first-party: not bought, not inferred, but shared by the prescribers themselves.
Prescribing in America™
SharePath’s findings are published each year in Prescribing in America™, from The Prescribing Institute, whose goal is to set the standard for how every prescriber in America is valued by 2030.
First-Party PoweredAbout SharePath, Inc.
SharePath is The Prescribing Intelligence Company, delivering first-party prescriber intelligence to pharmaceutical and biotechnology brands. Its Intelligence division offers NP/PA Census™, TargetMD™, PromptPoint™ and True ROI™. Its Engagement division, Health-Scripts®, is a network of 650,000+ verified clinicians. SharePath is headquartered in Cary, North Carolina. Learn more at www.sharepath.com.
Media contact
###